Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-23 pm EDT Pre-market 08:54:35 am
808.4 USD +0.69% Intraday chart for Eli Lilly and Company 813.2 +0.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915 MT
Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln RE
Radar Therapeutics announced that it has received $13.4 million in funding from NFX Capital Management, LLC, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors CI
Swiss Equities Tumble as UK Inflation Data Dampens June Rate Cut Hopes MT
Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment MT
China Grants Green Light to Eli Lilly's Diabetes Treatment MT
Eli Lilly Wins Chinese Approval for Diabetes Drug MT
Australia to ban knock-offs of popular weight-loss drugs Ozempic, Mounjaro RE
Health Care Up as Eli Lilly Hits Record High - Health Care Roundup DJ
Two US asset managers launch weight-loss ETFs RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... Our Logo
Eli Lilly: conclusive trial in Crohn's disease CF
Central bankers try to reason with investors Our Logo
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Eli Lilly and Company's Phase 3 Study of Mirikizumab to Treat Crohn's Disease Achieves 'Meaningful Improvements' MT
Eli Lilly Reports More than 50% Remission Rate in Crohn's Treatment Trial DJ
Eli Lilly Reportedly Gets Approval for Diabetes Drug Tirzepatide in China MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline MT
Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users RE
Eli Lilly's diabetes drug tirzepatide gets approval in China RE
Eli Lilly says its diabetes drug tirzepatide gets approval in China RE
US Equity Markets Close Mixed Monday After Fed Officials' Remarks MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Ease Monday Afternoon MT
Sector Update: Health Care MT
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
808.4 USD
Average target price
850.8 USD
Spread / Average Target
+5.24%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs